(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 August 2010 (26.08.2010)

PCT

(10) International Publication Number
WO 2010/094956 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 29/00* (2006.01)
A61P 11/00 (2006.01) *A61K 31/4162* (2006.01)

(21) International Application Number:
PCT/GB2010/050257

(22) International Filing Date:
16 February 2010 (16.02.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0902651.9 17 February 2009 (17.02.2009) GB
0908069.8 11 May 2009 (11.05.2009) GB

(71) Applicant *(for all designated States except US)*: **PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED.** [GB/GB]; Stoke Court, Stoke Poges, Slough, Berkshire SL2 4SY (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FINCH, Harry** [GB/GB]; Pulmagen Therapeutics (Inflammation) Limited, Stoke Court, Stoke Poges, Slough, Berkshire SL2 4SY (GB). **MONTANA, John** [GB/GB]; Pulmagen Therapeutics (Inflammation) Limited, Stoke Court, Stoke Poges, Slough, Berkshire SL2 4SY (GB). **VAN NIEL, Monique Bodil** [NL/GB]; Pulmagen Therapeutics (Inflammation) Limited, Stoke Court, Stoke Poges, Slough, Berkshire SL2 4SY (GB). **WOO, Chi-Kit** [GB/GB]; Pulmagen Therapeutics (Inflammation) Limited, Stoke Court, Stoke Poges, Slough, Berkshire SL2 4SY (GB). **KNIGHT, Jamie** [GB/GB]; Pulmagen Therapeutics (Inflammation) Limited, Stoke Court, Stoke Poges, Slough, Berkshire SL2 4SY (GB). **WASZKOWYCZ, Bohdan** [GB/GB]; Pulmagen Therapeutics (Inflammation) Limited, Stoke Court, Stoke Poges, Slough, Berkshire SL2 4SY (GB).

(74) Agent: **PERRY, Robert, Edward**; Gill Jennings & Every LLP, Broadgate House, 7 Eldon Street, London, Greater London EC2M 7LH (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2010/094956 A1

(54) Title: TRIAZOLOPYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS



(I)

(II)

(57) Abstract: Compounds of formula (I) are inhibitors of p38 MAP kinase, useful as anti-inflammatory agents in the treatment of, *inter alia*, diseases of the respiratory tract wherein; R^1 is C_1-C_6 alkyl, C_3-C_6 cycloalkyl, phenyl which is optionally substituted, 5- or 6 membered monocyclic heteroaryl which is optionally substituted, or a radical of formula (II) wherein n is 1 or 2, and R^3 and R^4 are independently H or C_1-C_6 alkyl, or R^3 and R^4 taken together with the nitrogen to which they are attached form a 6-membered heterocyclic ring optionally containing a further heteroatom selected from N and O; Y is -O- or -S(O)$_p$- wherein p is 0, 1 or 2; A is an optionally substituted divalent arylene radical, or a mono- or bicyclic heteroarylene radical, or a C_3-C_6 divale nt cycloalkylene radical having 5 or 6 ring atoms, or a piperidinylene radical wherein the ring nitrogen is linked to $R^2NHC(=O)W$-; W is a bond, -NH- or -C(R^A)(R^B), wherein R^A and R^B are independently H, methyl, ethyl, amino, hydroxyl or halo; and R^2 is a radical as defined in the claims.